| Literature DB >> 22086517 |
Bicheng Zhang1, Guoqing Yao, Yafei Zhang, Juan Gao, Bo Yang, Zhiguo Rao, Jianfei Gao.
Abstract
OBJECTIVES: Tumor-associated macrophages have been implicated in promoting tumor growth, progression and metastasis. However, the activated phenotype (M1 or M2) of tumor-associated macrophages remains unknown in solid tumors. Therefore, this study examined the density and prognostic significance of M2-polarized tumor-associated macrophages in lung adenocarcinoma.Entities:
Mesh:
Year: 2011 PMID: 22086517 PMCID: PMC3203959 DOI: 10.1590/s1807-59322011001100006
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
The relationships between TAM, M1- or M2-polarized TAM counts and clinicopathologic features (± s).
| Clinicopathologic features | Cases | TAMs | M1-polarized TAMs | M2-polarized TAMs | |||
| Gender | |||||||
| Male | 38 | 104.19±15.93 | 0.712 | 21.15±6.11 | 0.948 | 83.04±12.70 | 0.903 |
| Female | 27 | 103.07±15.74 | 20.61±5.73 | 82.15±11.26 | |||
| Age (yrs.) | |||||||
| ≥55 | 34 | 105.45±18.96 | 0.895 | 21.29±5.10 | 0.705 | 84.84±12.04 | 0.681 |
| <55 | 31 | 101.88±14.11 | 20.58±6.26 | 82.00±10.61 | |||
| Differentiation | |||||||
| Well-to-moderate | 36 | 103.17±15.15 | 0.984 | 20.63±6.96 | 0.157 | 82.23±10.43 | 0.645 |
| Poor | 29 | 103.98±11.67 | 20.80±6.16 | 82.87±10.17 | |||
| Lymph node metastasis | |||||||
| Positive | 35 | 120.44±35.83 | 0.042 | 24.09±4.56 | 0.882 | 95.99±15.60 | 0.003 |
| Negative | 30 | 94.26±14.52 | 18.85±7.27 | 70.26±12.16 | |||
| pTNM staging | |||||||
| I+II | 39 | 96.38±21.55 | 0.037 | 20.31±4.71 | 0.431 | 76.81±10.32 | 0.029 |
| III+IV | 26 | 115.49±30.94 | 23.45±5.35 | 92.05±18.14 |
Statistically significant.
Figure 1Th1/Th2 cytokine expression in fresh lung adenocarcinoma tissue and benign lung lesion homogenates (pg/ml). Fresh lung adenocarcinoma homogenates contained significantly more IL-4 and IL-10 than benign lung lesion homogenates. * p<0.01.
Figure 2M2- and M1-polarized TAMs in lung adenocarcinoma. (A) The coexpression of CD68 and MMR in TAMs in human lung adenocarcinoma sections. (B) The coexpression of CD68 and iNOS in TAMs in human lung adenocarcinoma sections.
Figure 3Peritumoral (A) and intratumoral LMVD (B) in lung adenocarcinoma samples. D2-40-positive staining was detected in lymph vessels by immunohistochemical staining (×400, SP method). The red arrow indicates the LMVD detected in lung tissues. (C) The LMVD of lung adenocarcinoma tissues and adjacent peritumoral tissues. * p<0.01.
Figure 4Kaplan-Meier curves for overall survival by TAM count (A) and M2-polarized TAM count (B) in patients with lung adenocarcinoma. A shows the difference in the overall survival rate between the high and the low TAM count groups (p<0.001). B shows the difference in the overall survival rate between the high and the low M2-polarized TAM groups (p<0.001).
Hazard ratios (HR), 95% confidence interval (CI) and p-value for the 65 patients with lung adenocarcinoma.
| Factor | HR | 95% CI | |
| Gender | 0.303 | 0.574 | 0.200-1.649 |
| Age | 0.393 | 1.317 | 0.700-2.480 |
| Differentiation | 0.670 | 1.175 | 0.558-2.476 |
| Lymph node metastasis | 0.011 | 2.778 | 1.260-6.123 |
| P-TNM staging | 0.039 | 3.021 | 1.055-8.649 |
| TAM count | 0.015 | 3.602 | 1.279-10.142 |
| M1-polarized TAMs count | 0.860 | 0.881 | 0.214-3.628 |
| M2-polarized TAMs count | 0.031 | 4.280 | 1.146-15.984 |
| Intratumoral LMVD | 0.327 | 1.189 | 0.841-1.679 |
| Peritumoral LMVD | 0.038 | 1.073 | 1.004-1.147 |
Statistically significant.